![Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction | Journal of the American College of Cardiology Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction | Journal of the American College of Cardiology](https://www.jacc.org/cms/asset/0174af37-6db2-4b29-924c-843fcdc2712f/fx1.jpg)
Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction | Journal of the American College of Cardiology
![Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison - The Lancet Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison - The Lancet](https://www.thelancet.com/cms/attachment/2000988127/2003634384/gr1.gif)
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison - The Lancet
![Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/63c765d9-c539-4d2f-8fde-eb1a58bf13e8/joim13505-gra-0001-m.jpg)
Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library
![Cardiovascular Risks of Nonsteroidal Antiinflammatory Drugs in Patients After Hospitalization for Serious Coronary Heart Disease | Circulation: Cardiovascular Quality and Outcomes Cardiovascular Risks of Nonsteroidal Antiinflammatory Drugs in Patients After Hospitalization for Serious Coronary Heart Disease | Circulation: Cardiovascular Quality and Outcomes](https://www.ahajournals.org/cms/asset/1a7cace3-4767-4dd0-a86c-7886e9c80050/6ff1.jpeg)
Cardiovascular Risks of Nonsteroidal Antiinflammatory Drugs in Patients After Hospitalization for Serious Coronary Heart Disease | Circulation: Cardiovascular Quality and Outcomes
![Painkiller heart attack risk: Don't stop taking Diclofenac pills but talk to your GP | Daily Mail Online Painkiller heart attack risk: Don't stop taking Diclofenac pills but talk to your GP | Daily Mail Online](https://i.dailymail.co.uk/i/pix/2011/09/27/article-2042619-0E1E204800000578-977_468x359.jpg)
Painkiller heart attack risk: Don't stop taking Diclofenac pills but talk to your GP | Daily Mail Online
![What is Diclofenac, what is the painkiller used to treat and how is it linked to heart attacks and strokes? | The Sun What is Diclofenac, what is the painkiller used to treat and how is it linked to heart attacks and strokes? | The Sun](https://www.thesun.co.uk/wp-content/uploads/2018/09/pmCOMPOSITEheart.jpg?strip=all&quality=100&w=750&h=500&crop=1)